Velactis
cabergoline
Table of contents
Suspended
This medicine is currently suspended from use in the European Union.
Overview
The marketing authorisation for Velactis has been suspended on the recommendation of the Agency's Committee for Medicinal Products for Veterinary Use (CVMP).
This EPAR was last updated on 04/10/2016
Authorisation details
| Product details | |
|---|---|
| Name |
Velactis
|
| Agency product number |
EMEA/V/C/003739
|
| Active substance |
cabergoline
|
| International non-proprietary name (INN) or common name |
cabergoline
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QG02CB03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Ceva Santé Animale
|
| Revision |
1
|
| Date of issue of marketing authorisation valid throughout the European Union |
09/12/2015
|
| Contact address | |
Product information
22/08/2016 Velactis - EMEA/V/C/003739 -
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
-
Genito urinary system and sex hormones
-
Other gynecologicals
-
Prolactine inhibitors
Therapeutic indication
Therapeutic indication
For use in the herd management programme of dairy cows as an aid in the abrupt drying-off by reducing milk production to:
- reduce milk leakage at drying off;
- reduce the risk of new intramammary infections during the dry period;
- reduce discomfort.